Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Ankylosing Spondylitis Market Size Forecast: How Large Could The Market Become By 2030?

The ankylosing spondylitis market demonstrated robust expansion recently, with projections indicating a rise from $6.34 billion in 2025 to $6.85 billion in 2026, reflecting a compound annual growth rate of 8.0%. This historical growth trajectory was underpinned by heightened diagnostic recognition, broader accessibility to non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), enhanced provision of specialized rheumatology care, expanded access to hospital-based treatments, and the increasing utilization of diagnostic imaging for tracking disease progression.

The ankylosing spondylitis market is poised for substantial expansion over the coming years, projecting a rise to $9.42 billion by 2030 with a compound annual growth rate of 8.3%. This anticipated increase during the forecast period is propelled by several key factors, including a greater acceptance of biologic and biosimilar treatments, an escalating emphasis on individualized medical care, the broadening of sophisticated biologic drug development, a growing need for sustained management of the condition, and increased funding allocated to autoimmune disease research. Prominent developments expected within this timeframe involve a heightened utilization of biologic treatments, a more frequent application of disease-modifying antirheumatic drugs (DMARDs) designed for specific targets, a greater commitment to identifying the disease in its early stages, the advancement of tailored therapeutic strategies, and a more comprehensive incorporation of physical therapy into patient care plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Ankylosing Spondylitis Market Industry Drivers: What Is Driving Revenue Growth?

The projected expansion of the ankylosing spondylitis market is anticipated to be propelled by the rising occurrence of autoimmune conditions. These conditions encompass a wide array of disorders marked by an aberrant immune system response where the body’s own defenses erroneously attack and harm healthy cells, tissues, and organs. Ankylosing spondylitis, classified as an autoimmune disease, arises when the immune system incorrectly directs its activity towards the body’s own tissues, resulting in inflammation and subsequent damage. While a genetic susceptibility and environmental influences play a role in the pathogenesis of ankylosing spondylitis, a type of autoimmune arthritis predominantly impacting the spinal column and pelvic region, further data underscores this trend. Specifically, the Impact of IBD Report 2023, released in September 2023 by the IBD Clinical and Research Centre in Canada, highlighted that in 2023, inflammatory bowel disease (IBD) affected 825 individuals per 100,000, impacting over 320,000 Canadians. Moreover, with an anticipated annual prevalence increase of 2.44%, it is estimated that by 2035, 1.1% of the Canadian populace, equating to 470,000 individuals, will be managing IBD. Consequently, the escalating rates of autoimmune diseases are poised to fuel the forthcoming growth trajectory of the ankylosing spondylitis market.

Ankylosing Spondylitis Market Segmentation And Category Breakdown

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

#Ankylosing Spondylitis Market Growth Trends: What Is Influencing The Future Outlook?

Within the ankylosing spondylitis market, leading corporations are concentrating their efforts on creating cutting-edge biologic treatments, including biosimilars, with the aims of improving patient accessibility, lowering healthcare expenditures, and offering established delivery methods. These biosimilars are medications that utilize the same active components as original biologic drugs but are designed to be just as effective and safe. To illustrate, in August 2025, Amgen Biotechnology Singapore, a biotechnology enterprise situated in Singapore, secured approval for its adalimumab biosimilar, known as Amgevita, available in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This treatment is prescribed to alleviate the signs and symptoms experienced by adult individuals suffering from active ankylosing spondylitis who have not responded adequately to standard treatments. This approach facilitates well-known administration pathways, capitalizes on a recognized active compound, and introduces a more economically viable choice within the biologics sector.

Ankylosing Spondylitis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Access The Complete Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Ankylosing Spondylitis Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model